Budha Nageshwar - Department of Clinical Pharmacology, Genentech, Inc

Jayesh Desai, Peter Fong, Victor Moreno, Sophia Frentzas,Tarek Meniawy, Ben Markman,Mark Voskoboynik, Tahmina Rahman,Nageshwar Budha, John Wu, Jin Marlow, Silu Yang,

British Journal of Cancerno. 8 (2023): 1418-1428

Cited0Views0Bibtex

Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies

Dmitry Shchelokov,Oleg Demin,Oleg Demin,Ahsan Rizwan, Yun Zhang,Wei Tan,Srikumar Sahasranaman,Nageshwar Budha

CANCER RESEARCHno. 12 (2022)

Cited0Views0Bibtex

Peripheral pharmacodynamic (pd) effects of ociperlimab (oci) in combination with tislelizumab (tis) in patients with advanced solid tumors: advantig-105 phase 1 doseescalation study

Wei Tan,Yang Shi, Han Yan,Zhirong Shen,Nageshwar Budha,Ahsan Rizwan,Ruiqi Huang, Hao Zheng,Rang Gao,Sophia Frentzas,Steven Kao,Tarek Meniawy,

Regular and Young Investigator Award Abstracts (2022): A799-A799

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn